Rwanda takes swift action to vaccinate healthcare workers amid Marburg Outbreak

On Sunday, October 6, 2024, Rwanda begins its vaccination campaign against the Marburg virus, with healthcare workers at the forefront of this effort. As the country faces a growing outbreak, the government is focusing on protecting those most vulnerable—particularly medical personnel directly involved in treating infected patients.

In a press briefing, Minister of Health Dr. Sabin Nsanzimana revealed that 700 doses of the Marburg vaccine had arrived in Rwanda on October 5, 2024. The vaccines have already passed thorough inspections by health authorities, paving the way for immediate distribution.

“Our priority is to safeguard the frontline workers who are putting their lives at risk every day to treat those infected, we will start with healthcare staff, especially those working in intensive care units and emergency services, where the chances of exposure are highest,” Dr. Nsanzimana explained.

Dr. Nsanzimana emphasized that protecting these workers is critical to the overall success of the outbreak response.

“These individuals are the backbone of our healthcare system. Ensuring their safety means they can continue to provide care for others without putting themselves at risk,” he added.

In addition to healthcare workers, individuals who have had close contact with infected patients will also receive the vaccine.

“Vaccination is the key strategy here to limit further spread, especially for those who may have already been exposed,” the Minister noted.

Rwanda’s swift response to the outbreak has been praised, particularly the rapid delivery of the vaccine, known as ‘Sabin’s vaccine,’ which has also been used in previous Marburg outbreaks in countries such as Uganda and Kenya.

“While the vaccine arrived just a week after the outbreak was identified, we’re grateful for the international collaboration that made this possible,” said Dr. Nsanzimana.

As of now, Rwanda has reported 46 confirmed cases of the virus, with 29 patients still undergoing treatment. The death toll has reached 12, while five individuals have recovered. Encouragingly, three more patients are showing signs of recovery, and additional tests will determine if they can be discharged soon.

To support patient recovery, Rwanda is also utilizing Remdesivir, a medication known for its ability to inhibit viral growth. First used during the COVID-19 pandemic, Remdesivir has shown promise in treating Marburg patients.

“We are seeing positive outcomes, especially for those who received the treatment early in their diagnosis,” Dr. Nsanzimana confirmed.

Alongside this, Monoclonal antibodies are being administered to further boost patients’ immune responses.

The government’s decisive action, including targeted vaccinations and innovative treatment options, is aimed at containing the outbreak and preventing further deaths.

Rwanda remains committed to safeguarding both its healthcare workers and its population as the fight against Marburg continues.